Pfizer veteran AMY SCHULMAN has big pharma experience, but in Boston she discovered
her startup side. In 2014, she moved to Boston and joined Polaris Partners
as a venture partner and became CEO of Arsia Therapeutics. Arsia was acquired
in 2016, and Schulman is now CEO of drug-delivery startup Lyndra. She also teaches
leadership and corporate accountability at Harvard Business School. Schulman spoke with Xconomy
about adjusting to life in Boston biotech.
Amy Schulman, Lyndra • Photography by Alex Gagne and Rythum Vinoben